Q4 2024 Management View CEO Mihael Polymeropoulos highlighted strong revenue growth for Fanapt, driven by its launch for bipolar I disorder and increased new-to-brand prescriptions by over 160% ...
Keeping a Buy rating and $155 price target on Blueprint Medicines (BPMC), Stifel says the market is disappointed that 2025 Ayvakit guidance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback